AUSTIN, Texas--(BUSINESS WIRE)--Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at an initial public offering price of $10.00 per share. The shares are expected to begin trading on The NASDAQ Global Market on April 7, 2016 under the symbol “AGLE.” In addition, Aeglea has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.
UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities are acting as joint book-running managers for the offering. Needham & Company is acting as co-manager.
A registration statement relating to these securities was filed with the Securities and Exchange Commission and declared effective on April 6, 2016. The offering is being made only by means of a prospectus, copies of which may be obtained from the offices of UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone: (888) 827-7275; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, or by telephone: (800) 414-3627, or by email: email@example.com; or Wells Fargo Securities, LLC, 375 Park Avenue, New York, NY 10152, Attention: Equity Syndicate Department, or by telephone: (800) 326-5897, or by email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.